FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain
Concentric Analgesics, Inc.
Biotechnology Research
San Francisco, California 1,114 followers
Our mission is to dramatically improve the lives of patients by developing breakthrough non-opioid pain therapeutics.
About us
Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.
- Website
-
https://www.concentricanalgesics.com/
External link for Concentric Analgesics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2014
Locations
-
Primary
Get directions
101 California Street
Suite 1210
San Francisco, California 94111, US
Employees at Concentric Analgesics, Inc.
Updates
-
Concentric Analgesics, Inc. reposted this
In this podcast Drs. Jim Rathmell, David Clark, and Steven Shafer discuss the positive results of the Phase 2/3 study of #vocacapsaicin for postsurgical pain published this month in ANESTHESIOLOGY. https://lnkd.in/ebt4Hmvx American Society of Anesthesiologists®, Concentric Analgesics, Inc.
Featured Author Podcast: Vocacapsaicin for Postsurgical Pain
https://www.libsyn.com
-
Concentric Analgesics, Inc. reposted this
Had some great engagement at the Concentric Analgesics, Inc. poster presentation at #WC2024 in Amsterdam thanks to David Leiman, MD, MBA and Harold Minkowitz, MD for supporting surgical questions that were very much not in my lane and everyone else that stopped by. #TRPV1 pathway continues to show great promise in pain management and John Donovan, MD, MBA and his crew at Concentric have some great results in these completed studies.
Announcing Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids — Concentric Analgesics, Inc.
concentricanalgesics.com
-
Concentric Analgesics Presents Data Highlighting Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures at the International Association for the Study of Pain (IASP) World Congress. https://lnkd.in/gcKJp8Wm
Concentric Analgesics Announces Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures
businesswire.com
-
Concentric Analgesics, Inc. reposted this
Excited that Concentric Analgesics, Inc. is presenting clinical results for vocacapsaicin today at the International Association for the Study of Pain (IASP) World Congress in Amsterdam. https://lnkd.in/g3D6kEQr David Leiman, MD, MBA, Ben Vaughn, Harold Minkowitz, MD
-
-
congrats to the team on another important milestone validating the potential of our non-opioid pain therapeutic, poised to begin phase 3 studies.
Concentric Analgesics Announces Data Highlighting Two Weeks of Durable Pain Relief and Earlier Cessation of Opioids in Two Surgical Procedures
businesswire.com
-
Concentric Analgesics is pleased to announce vocacapsaicin, our non-opioid drug candidate for postsurgical pain is featured on the cover of the current issue of ANESTHESIOLOGY, the journal that leads leads the world in publication of peer-reviewed research that transforms clinical practice and fundamental understanding in #anesthesiology. https://lnkd.in/gzeXzRDj This is a huge affirmation of the efficacy, importance and potential of vocacapsaicin to reduce the reliance on opioids after surgery.
-